Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC
Recruiting
Observational Study
Non Small Cell Lung Cancer
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 70 (estimated)
- Sponsor
- Hunan Province Tumor Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
* Potentially Resectable NSCLC
* Treatment Plan is Crizotinb or Standard Chemotherapy
Exclusion Criteria:
* Patients with contraindication of chemotherapy
* Pregnant or breast feeding women
Contacts